Glimepiride-d<sub>4</sub>

Glimepiride-d4

CAT N°: 27846
Price:

348.00 295.80

Glimepiride-d4 is intended for use as an internal standard for the quantification of glimepiride (Item No. 12090) by GC- or LC-MS. Glimepiride is a long-acting sulfonylurea that inhibits ATP-sensitive potassium (KATP) channels in pancreatic ?-cells (IC50 = 3 nM), which leads to the release of insulin.{25521} At 20 ?M, glimepiride has been shown to increase the activity of intracellular insulin receptors and to prevent insulin receptor downregulation during chronic insulin stimulation through a mechanism involving protein kinase C activation.{25523} It has been reported to be less effective at inhibiting nonpancreatic KATP channels, and therefore contributes fewer cardiac actions, compared to earlier generations of sulfonylurea anti-type 2 diabetes treatments.{25522}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 3-ethyl-4-methyl-N-(2-(4-(N-((4-methylcyclohexyl)carbamoyl)sulfamoyl)phenyl)ethyl-1,1,2,2-d4)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
  • Correlated keywords
    • K-ATP Amaryl Glista OD GlistaOD diameprid dibiglim glimax glirid HOE 490 HOE490 pancreas
  • Product Overview:
    Glimepiride-d4 is intended for use as an internal standard for the quantification of glimepiride (Item No. 12090) by GC- or LC-MS. Glimepiride is a long-acting sulfonylurea that inhibits ATP-sensitive potassium (KATP) channels in pancreatic ?-cells (IC50 = 3 nM), which leads to the release of insulin.{25521} At 20 ?M, glimepiride has been shown to increase the activity of intracellular insulin receptors and to prevent insulin receptor downregulation during chronic insulin stimulation through a mechanism involving protein kinase C activation.{25523} It has been reported to be less effective at inhibiting nonpancreatic KATP channels, and therefore contributes fewer cardiac actions, compared to earlier generations of sulfonylurea anti-type 2 diabetes treatments.{25522}

We also advise you